



3Q FY2006

(Fiscal Year Ending March 31, 2007)

Financial Results Presentation

February 2, 2007







Safe Harbor Statement

 Materials and information provided during this presentation may contain socalled "forward-looking statements." These statements are based on current expectations, forecasts and assumpti





Consolidated Performance

(billions yen, %)

	Apr-Dec	2005	1	Apr-Dec	2006	
	Results	%	Results	%	YOY(%)	Increase (Decrease)
Net Sales	449.9	100.0	500.8	100.0	111	50.9
Cost of Sales	78.7	17.5	81.9	16.4	104	3.3
Gross Margin	371.2	82.5	418.9	83.6	113	47.6
R&D Expenses	67.0	14.9	78.9	15.8	118	11.8
SG&A Expenses	226.0	50.2	256.1	51.1	113	30.2
Operating Income	78.2	17.4	83.8	16.7	107	5.6
Ordinary Income	81.4	18.1	87.8	17.5	108	6.4
Net Income	52.2	11.6	55.8	11.2	107	3.7
R&D + Operating Income	145.2	32.3	162.7	32.5	112	17.5





Sales of Major Products

		Apr-Dec 2005	Apr-Dec	2006
		Results	Results	YOY(%)
	Total	142.6	182.7	128
	Japan	32.6	37.9	116
	US	84.3	114.5	136
AcipHex	Total Japan	114.0 21.7	130.9 23.7	115 109
Zonegran ® Anti-epileptic Drug	Total US \$million	11.5 11.2 100	3.7 2.5 22	33 23 22





Operating Income by Geographic Area


	Apr-Dec	2005		Apr-De	c 2006	
	Results	%	Results	%	YOY(%)	Increase (Decrease)
Japan	63.6	74.8	57.7	67.6	91	(5.9)
			21.4	25.1	135	5.6
				4.0	101	0.0
				3.3	128	0.6
				32.4	129	6.2
Sub-total	85.1	100.0	85.4	100.0	100	0.3
Elim1 37.1460 0.2 0	22e6					

107



Status of Major Projects (1)

- E7389 (USAN: eribulin mesylate) Microtubule growth suppressor (Target Subpart H NDA submission for breast cancer in 3Q FY2007)
 - Study for 3rd line Subpart H ongoing (enrollment completed)
 - Phase III study ongoing for 2nd line breast cancer treatment
 - Phase III study ongoing for 3rd line breast cancer treatment
 - Prostate cancer Phase II POC study ongoing
 - NSCLC Phase Ib study in combination with carboplatin ongoing
 - Initiated Sarcoma Phase II POC study
 - Phase I study ongoing in Japan



Green: Microtubule Blue: Chromosome







Status of Major Projects (2)

- **E2007** (USAN: perampanel): **AMPA receptor antagonist** (Target submission for Parkinson's disease: FY2007)
 - Parkinson's disease: Phase III studies ongoing in EU and US for on schedule submission (enrollment completed in one of three studies)
 - Migraine prophylaxis: Phase II POC study ongoing
 - Epilepsy: Phase II POC study ongoing
 - Multiple sclerosis: Phase II POC study in preparation
- **E5564** (INN: eritoran 4Na): Endotoxin antagonist (Target submission: FY2009 in JP, EU and US)
- Endotoxin

 LipidA →

- Phase III study ongoing for severe sepsis
 Sites open and patient enrollment on schedule
- Phase I study ongoing with Japanese volunteers in the US before conducting Phase III study in Japan





Area	Project	Mode of Action	Target Indication	Current Status	
	rufinamide INOVELON®		Lennox-Gastaut Syndrome (LGS)	Received marketing authorization as an orphan drug from the European Commission on January 16, 2007	Approved
			LGS & Epilepsy		
			Parkinson's disease		
			Migraine prophylaxis		
			Epilepsy		
			Multiple sclerosis		
			Diabetic neuropathy Amyotrophic lateral sclerosis		
			Alzheimer's disease		
			Breast cancer		
			Prostate cancer		
			NSCLC		
Oncol			Sarcoma		
Oncol-			Cancer		
ogy			Cancer Small cell lung cancer, pancreatic		
			cancer		
			Cancer		
			Cancer		
	T-614	Suppression of lymphocyte proliferation, immunoglobulin and inflammatory cytokines production		NDA submitted in September 2003 (Japan)	Submitted
		Fully human anti-TNF-alpha monoclonal	Rheumatoid arthritis	NDA submitted in December 2005 (Japan)	Submitted
	D2E7	antibody	Psoriasis	Phase II/III study ongoing	FY2007
		-	Crohn's disease	Initiated Phase II/III study	
				Phase III study ongoing for severe sepsis Site open and patients enrollment on schedule	FY2009
	E5564	Endotoxin antagonist	Severe sepsis	Phase I study ongoing using Japanese volunteers in the US, before conducting Phase III in Japan Plan to submit simultaneously in the US, Europe and Japan in FY2009	(Japan, US EU)
	E2014	Botulinum toxin type B	Cervical dystonia	NDA submitted in December 2006 (Japan)	Submitted
	KES524	Central acting serotonin & noradrenaline reuptake inhibitor	Obesity management	Phase III study ongoing	FY2007
	clevudine	·	Tc 0.00upo.C Tc T	Гс 0.00upo.C Тс Тс.10(i)9(a)] J0.00il3t 203 Td/5e2 TmJ-n7st214(e)2(ry)14(ongou009y)14(l	u 7r 9 -18rie (im





Product Target Indication

Severe Alzheimer's disease

Approved (US) Submitted (JP & EU)

Enriched NME & LCM Projects Filings & Approval in Japan



Approval		• •	•
Pariet [®]	Proton pump inhibitor	H. pylori eradication	Approval received in Jan. 2007
Filing			
T-614	Suppression of lymphocyte proliferation, immunoglobulin and inflammatory cytokines production	Rheumatoid arthritis	Submitted in Sept. 2003
D2E7	Fully human anti-TNF- alpha monoclonal antibody	Rheumatoid arthritis	Submitted in Dec. 2005
E2014	Botulinum toxin type B	Cervical dystonia	Submitted in Dec. 2006
Tambocor®	Na+ channel suppression	Paroxysmal atrial fibrillation/flutter	Submitted in Dec. 2004
Aricept®	Acetylcholinesterase inhibitor	Severe Alzheimer's disease	Submitted in Dec. 2005
————Pariet®	Droton numn inhihitar	Symptomatic GERD	Submitted in Mar. 2006
Panel	Proton pump inhibitor	H. pylori secondary eradication	Submitted in Aug. 2006
Vasolan [®]	Ca ⁺⁺ channel antagonist	Paroxysmal supraventricular tachycardia(PSVT)	Submitted in Jan. 2007
lomeron®	Nonionic contrast medium	Dosage and administration addition for lomeron 350	Plan to submit in FY2006
Filings plan	nned in FY2007		
D2E7	Fully human anti-TNF- alpha monoclonal antibody	Psoriasis	Plan to submit in FY2007
KES524	Central acting serotonin & noradrenaline reuptake inhibitor	Obesity management	Plan to submit in FY2007
Aricept®	Jelly formulation	Alzheimer's disease	Plan to submit in FY2007





Recorded




Over 30% Sales Growth in US

First and Only Full Spectrum AD Treatment

Improve call effectiveness by communicating clinical benefits across full spectrum of AD (Mild, Moderate and Severe) Achieved the highest Share of Voice in last 3 years among all AD therapies in November

Raising awareness among caregivers by implementing DTC and educational programs about importance of proper diagnosis and persistent treatment

Enhancement of marketing systems and promotions for the growing Long Term





Accelerate the Development of Oncology Franchise (1)



Top Priority in Dramatic Leap Plan

Discovery Research

Tsukuba Laboratories and Boston Laboratories serve as basic discovery research bases for oncology

Development

Global ilnitiative taken by Eisai Global Clinical Development (Based in US)

Production

New oncology facilities

 Broke ground in November 2006 for formulation research and new production facility in North Carolina, US for future global supply of oncology treatment

Investment: \$90 Million

Facility area: 65,000 square feet

Encompasses aseptic processing suites, laboratories and other support functions

 API manufacturing plant (P1 building) completed at Kashima Plant in November 2006



New discovery research building at Boston Laboratories





Accelerate the Development of Oncology Franchise (2)



Top Priority in Dramatic Leap Plan


Sales and Marketing

- Established "Eisai Oncology Franchise Office" in San Diego in December 2006
- The hospital-team, hoping for additional indication on Fragmin[®], start training programs to expand into oncology market
 Hospital-team and sales reps from Ligand will promote oncology products
 (FY2011 target: 300 oncology sales reps in US)



Advisory Board

 Ongoing Advisory Board Meeting for cutaneous T-cell lymphoma (indication of ONTAK® and Targretin®) and started communication with key opinion leaders including dermatologists and oncologists



Acquire oncology expert and know how from Ligand Pharmaceuticals
Academic meetings, distribution, reimbursement and FDA correspondence

Better Established for Market Entry of E7389

Progress of European Business

Expanding Market & New Products

- Inovelon®
 - Received marketing authorization as an orphan drug from the European Commission on January 16, 2007
 - Aim to launch *Inovelon*[®] in UK and Germany in 1Q FY2007



- Newly launched in Switzerland and Norway (November), Italy (December)
 Sales doing well in 12 European countries
- Plan to launch across other European countries
- Established a sales subsidiary in Portugal on November 3, 2006
- Plan to enter Benelux countries (Belgium, Netherlands, Luxemburg) in FY2007
- Expansion to rapidly growing countries; Central & Eastern Europe and Russia (FY2007)
 - Plan to open representative offices in Poland, Czech Republic, Slovakia and Hungary
 - Plan to open representative a office in Russia

4th Value Creation Base - India

Progressing Transformation Strategy

Function	Summary
Discovery	Discover treatments for neglected disease
Clinical Data Analysis	Global data management, biostatistics function
R & D API / Formulation Manufacturing	Equip process and formulation research functions and establish stable supply base for global market (Vizag)
Sales & Promotion	Established "Eisai Pharmaceuticals India Private Limited" in Mumbai in Oct. 2004

Research & Mfg. Company:

Eisai Pharmatechnology & Manufacturing Pvt. Ltd

Location: Vishakhapatnam, Andhra Pradesh States

Vizag Industrial Estate


Space 202,000 m²

Invest Amount: ¥5 billion

Employees 130 people

Operation: FY2010

Sales & Promotion
Research & Mfg





Japan Business Topics

- Eisai performs well in the tough Japanese market after NHI price revision
 - FY2006 average price reduction of over 7% (against FY2005 results)
 on Eisai prescription pharmaceuticals in Japan
 - Aricept®: approx. 6%
 - Pariet[®]: 15%
 - Sales of prescription pharmaceuticals in Japan : ¥168.7 billion (YTD Sales), 2% growth
 - Eisai grown 1% in IMS base, surpass 2 points in growth against market average
- OTC Business keeps 8% growth

(Aim to achieve 20% operating margin ratio in FY2011)

- OTC business maintains 8% growth in YTD sales over the previous year in flat growth market
 - Operating income ratio is achieved in the mid-teen percentage growth

Financial Forecast for FY2006 (billions yen,%)

	FY20	05	F	Y2006		Forecast
	Results	%	Forecast	%	YOY	Revision Since Oct.
Net Sales	601.3	100.0	668.0	100.0	111	15.0
Cost of Sales	104.5	17.4	110.0	16.5	105	1.0
Gross Margin	496.7	82.6	558.0	83.5	112	14.0
R&D Expenses	93.2	15.5	107.0	16.0	115	2.0
SG&A Expenses	307.8	51.2	344.0	51.5	112	10.0
Operating Income	95.7	15.9	107.0	16.0	112	2.0
Ordinary Income	100.0	16.6	111.0	16.6	111	2.5
Net Income	63.4	10.5	70.0	10.5	110	1.5

Original Forecast in May
640.0
101.0
101.0

234.4